Alnylam, Regeneron form $1B partnership to develop eye, central nervous system drugs
The deal will focus on discovery, development and commercialization of CNS and eye drugs and also includes development of two C5-targeting drugs in liver disease. The companies have an existing partnership centered on NASH drugs.